John P. Hamill Aprea Therapeutics, Inc. (APRE) insider trading activity

John P. Hamill is SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, Inc.. Currently has a direct ownership of 27,733 shares of APRE, which is worth approximately $33,556. The most recent transaction as insider was on Dec 10, 2025, when has been sold 5,000 shares (Common Stock) at a price of $1.17 per share, resulting in proceeds of $5,850. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 27.7K

21.99% 3M change

43.19% 12M change

Total Value Held $33,556

John P. Hamill Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 10 2025	BUY Open market or private purchase	$5,850 $1.17 p/Share	5,000 Added 15.28%	27,733 Common Stock
Mar 27 2025	BUY Grant, award, or other acquisition	-	3,365 Added 12.89%	22,733 Common Stock
Oct 11 2024	BUY Open market or private purchase	$123 $2.46 p/Share	50 Added 0.26%	19,368 Common Stock
Oct 10 2024	BUY Open market or private purchase	$1,174 $2.61 p/Share	450 Added 2.28%	19,318 Common Stock
Mar 28 2024	BUY Grant, award, or other acquisition	-	3,365 Added 15.14%	18,868 Common Stock
Mar 13 2024	BUY Open market or private purchase	$7,362 $7.29 p/Share	1,010 Added 6.12%	15,503 Common Stock
Feb 27 2023	BUY Grant, award, or other acquisition	$5,250 $5.25 p/Share	1,000 Added 6.45%	14,493 Common Stock

Jan 30 2023	BUY Grant, award, or other acquisition	-	269,879 Added 50.0%	269,879 Common Stock

Also insider at

WINT

WINDTREE THERAPEUTICS INC Healthcare

SVP & CFO

JPH

John P. Hamill

SrVP/CFO/Prin Fin & Acct Ofcr

Warrington, PA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APRE shares.

Notify only if

Value

Insider Trading

Get notified when an Aprea Therapeutics, Inc. insider buys or sells APRE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aprea Therapeutics, Inc.

Track Activities on APRE

Account